Saudi Chemical’s pharma segment profit margins range 30%-40%; seeks to add 30 new products: CEO

Thamer AlMuhid, CEO of Saudi Chemical Company Holding

Saudi Chemical Company Holding’s (SCCH) profit margins range between 30% and 40% for the pharmaceutical segment, with net profit of 15-18%, Al Ekhbariya TV reported, citing CEO Thamer AlMuhid. 

“These levels in the local market are lower compared to peers in the international market due to abundant active ingredients there,” AlMuhid noted.  

SCCH subsidiary, AJA Pharmaceutical Industries Co. (AJA Pharma), has four production lines as well as seven packaging lines. It will add a new production line for the sterile preparations by mid-2023, which will allow manufacturing insulin and cancer medications. 

AlMuhid also indicated that the company seeks to add 30 new pharmaceutical preparations over the coming four years.  

SCCH, through AJA Pharma, announced on Nov. 20, the start of the initial manufacturing steps towards commercializing “Panadol Extra”, one of Haleon (GSK consumer healthcare) products, Argaam reported.